Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation

No abstract is available for this paper.

• Publication year

  2022

• Venue

  European journal of drug metabolism and pharmacokinetics

• Publication date

  2022-02-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s13318-021-00740-xPMID 35147853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Human UDP-Glucuronosyltransferase Enzyme by Dabrafenib: Implications for Drug-Drug Interactions.

  2021cited by this paper
• Label

  2020cited by this paper
• The pharmacokinetic interaction between irinotecan and sunitinib

  2019cited by this paper
• Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

  2019cited by this paper
• Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinb and BIBF 1202.

  2019cited by this paper
• Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma

  2018cited by this paper
• Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

  2018cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib

  2018cited by this paper
• UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine.

  2017cited by this paper
• The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes

  2015cited by this paper
• Inhibition of SN-38 glucuronidation by gefitinib and its metabolite

  2015cited by this paper
• Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases

  2015cited by this paper
• Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

  2015cited by this paper
• Quantification of the impact of enzyme‐inducing antiepileptic drugs on irinotecan pharmacokinetics and SN‐38 exposure

  2015cited by this paper
• Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

  2014cited by this paper
• The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk

  2014cited by this paper
• UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• New drugs in melanoma: it's a whole new world.

  2011cited by this paper
• Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases

  2010cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007cited by this paper
• The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

  2007cited by this paper
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007cited by this paper
• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  2004cited by this paper
• 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.

  2004cited by this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cited by this paper
• Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

  2003cited by this paper
• Determinants of BRAF mutations in primary melanomas.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia.

  2002cited by this paper
• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

  2002cited by this paper
• The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.

  2002cited by this paper
• Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

  2001cited by this paper
• Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

  1999cited by this paper
• UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.

  1998cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

  1997cited by this paper
• Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis

  1996cited by this paper
• Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.

  1996cited by this paper
• The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

  1995cited by this paper
• Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11

  1993cited by this paper
• Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.

  1992cited by this paper

• Potent and highly selective inhibition of selpercatinib towards UDP-glucuronosyltransferase 1A4 (UGT1A4) isoform.

  2025cites this paper
• Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1.

  2024cites this paper
• Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases.

  2023cites this paper
• A method of isolating and analysing drugs from cancer cells for preclinical research.

  2022cites this paper
• Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins.

  2022cites this paper